Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.

PubWeight™: 1.81‹?› | Rank: Top 3%

🔗 View Article (PMID 17186290)

Published in Cancer Immunol Immunother on December 22, 2006


Juro Nakanishi1, Yoshihiro Wada, Koichiro Matsumoto, Miyuki Azuma, Ken Kikuchi, Shoichi Ueda

Author Affiliations

1: Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Honjo, Kumamoto, Japan.

Articles citing this

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood (2015) 1.80

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther (2014) 1.58

Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS One (2011) 1.55

PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One (2015) 1.45

Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One (2013) 1.44

Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One (2011) 1.38

Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28

Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer (2009) 1.12

Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol (2011) 1.12

The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09

The immunomodulatory glycan LNFPIII initiates alternative activation of murine macrophages in vivo. Immunology (2008) 1.08

Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy (2010) 1.06

Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol (2015) 1.02

Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol (2013) 1.02

The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol (2014) 1.01

Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01

The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol (2009) 0.99

PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther (2016) 0.98

Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology (2015) 0.98

Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J (2012) 0.97

Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 0.96

Immune checkpoint inhibitors: a new frontier in bladder cancer. World J Urol (2015) 0.87

Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J (2011) 0.86

Emerging Co-signaling Networks in T Cell Immune Regulation. Immune Netw (2013) 0.86

Immunotherapy for bladder cancer. Res Rep Urol (2015) 0.86

PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol (2016) 0.85

Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther (2015) 0.84

Unexpected acceleration of type 1 diabetes by transgenic expression of B7-H1 in NOD mouse peri-islet glia. Diabetes (2010) 0.83

Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci (2017) 0.82

Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy. BMC Immunol (2015) 0.81

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget (2016) 0.81

Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Cancer Immunol Res (2016) 0.81

Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. Am J Transl Res (2016) 0.81

The current status of checkpoint inhibitors in metastatic bladder cancer. Clin Exp Metastasis (2016) 0.81

Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol (2015) 0.81

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med (2015) 0.80

Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression. Oncol Lett (2013) 0.80

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol (2016) 0.80

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget (2017) 0.79

Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer (2016) 0.79

Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLoS One (2015) 0.78

New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clin Cancer Res (2015) 0.78

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest New Drugs (2016) 0.78

Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy (2016) 0.77

Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy (2009) 0.77

New developments in the management of advanced melanoma - role of pembrolizumab. Onco Targets Ther (2015) 0.77

Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol (2016) 0.77

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) (2017) 0.76

Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs (2014) 0.76

Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. Ther Adv Urol (2016) 0.75

CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Oncotarget (2016) 0.75

The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma. Bladder Cancer (2016) 0.75

Evolving immunotherapy strategies in urothelial cancer. Am Soc Clin Oncol Educ Book (2015) 0.75

Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer. Urol Clin North Am (2015) 0.75

Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PLoS One (2017) 0.75

Immunotherapy in urothelial carcinoma: fade or future standard? Transl Androl Urol (2016) 0.75

Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. J Gastric Cancer (2016) 0.75

Nonmuscle invasive bladder cancer: a primer on immunotherapy. Cancer Biol Med (2016) 0.75

PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett (2017) 0.75

PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. Oncotarget (2017) 0.75

Regulation of cytotoxic T-cell responses by p53 in cancer. Transl Cancer Res (2016) 0.75

Articles by these authors

Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res (2004) 4.65

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41

The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18

Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 2.58

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34

Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood (2009) 2.27

Reclassification of phenotypically identified staphylococcus intermedius strains. J Clin Microbiol (2007) 2.23

SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med (2003) 2.20

A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13

The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology (2004) 2.02

Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol (2004) 1.86

Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med (2003) 1.85

Niflumic acid suppresses interleukin-13-induced asthma phenotypes. Am J Respir Crit Care Med (2006) 1.79

Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci U S A (2008) 1.77

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood (2010) 1.77

Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol (2005) 1.76

Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J Infect Chemother (2008) 1.72

Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur J Immunol (2003) 1.69

Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.62

B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J Immunol (2004) 1.61

Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol (2005) 1.58

Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol (2003) 1.57

Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation (2007) 1.56

PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol (2009) 1.56

Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol (2006) 1.54

B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol (2006) 1.52

Methicillin-resistant Staphylococcus pseudintermedius in a veterinary teaching hospital. J Clin Microbiol (2007) 1.51

PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol (2007) 1.51

Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun (2003) 1.49

Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells. J Immunol (2011) 1.47

Detection of new methicillin-resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1 gene responsible for hospital- and community-acquired infections in France. J Clin Microbiol (2006) 1.46

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 1.44

The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells. Nat Immunol (2011) 1.41

Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease. J Immunol (2006) 1.35

Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol (2008) 1.32

Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother (2005) 1.31

Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res (2009) 1.31

B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem Biophys Res Commun (2007) 1.29

BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood (2003) 1.26

Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol (2009) 1.26

Effect of interferon-gamma on allergic airway responses in interferon-gamma-deficient mice. Am J Respir Crit Care Med (2002) 1.24

Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J Immunol (2009) 1.23

Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J Immunol (2005) 1.20

Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2008) 1.18

Infective endocarditis by Bartonella quintana masquerading as antineutrophil cytoplasmic antibody-associated small vessel vasculitis. Cardiology (2009) 1.18

Unraveling the ischemic brain transcriptome in a permanent middle cerebral artery occlusion mouse model by DNA microarray analysis. Dis Model Mech (2011) 1.18

Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol (2002) 1.16

Circadian control of chloroplast transcription by a nuclear-encoded timing signal. Science (2013) 1.16

A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci (2012) 1.16

Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation (2008) 1.16

Genetic engineering of group 2 sigma factor SigE widely activates expressions of sugar catabolic genes in Synechocystis species PCC 6803. J Biol Chem (2011) 1.15

Genetic diversity of staphylocoagulase genes (coa): insight into the evolution of variable chromosomal virulence factors in Staphylococcus aureus. PLoS One (2009) 1.14

Successful treatment of Aspergillus peritonitis in a peritoneal dialysis patient. Pediatr Nephrol (2002) 1.12

A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol (2007) 1.12

Prospective surveillance of community-onset and healthcare-associated methicillin-resistant Staphylococcus aureus isolated from a university-affiliated hospital in Japan. Microbiol Immunol (2005) 1.11

Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. Arterioscler Thromb Vasc Biol (2004) 1.11

Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun (2010) 1.11

Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol (2007) 1.11

Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun (2007) 1.10

The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol (2011) 1.10

Differential regulation by glucocorticoid of interleukin-13-induced eosinophilia, hyperresponsiveness, and goblet cell hyperplasia in mouse airways. Am J Respir Crit Care Med (2003) 1.08

Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness. J Exp Med (2005) 1.07

Candidemia Diagnosed from Peripheral Blood Smear: Case Report and Review of Literature 1954-2013. Mycopathologia (2015) 1.07

Pathogenesis of murine experimental allergic rhinitis: a study of local and systemic consequences of IL-5 deficiency. J Immunol (2002) 1.06

Quantitative and qualitative comparison of virulence traits, including murine lethality, among different M types of group A streptococci. J Infect Dis (2003) 1.06

Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance. Blood (2010) 1.04

PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes. Diabetes (2013) 1.04

Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol (2003) 1.04

Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells. Mol Ther (2008) 1.02

Increased prevalence of interleukin-17-producing CD4(+) tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck (2010) 1.02

Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol (2005) 1.01

Inhibition of STAT3 prevents neointima formation by inhibiting proliferation and promoting apoptosis of neointimal smooth muscle cells. Hum Gene Ther (2003) 1.00

Streptococcus dysgalactiae-derived mitogen (SDM), a novel bacterial superantigen: characterization of its biological activity and predicted tertiary structure. Mol Microbiol (2003) 0.99

Exogenous coproporphyrin III production by Corynebacterium aurimucosum and Microbacterium oxydans in erythrasma lesions. J Med Microbiol (2011) 0.99

Sugar catabolism regulated by light- and nitrogen-status in the cyanobacterium Synechocystis sp. PCC 6803. Photochem Photobiol Sci (2007) 0.99

Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells. Biochem Biophys Res Commun (2006) 0.99

Programmed death-1-programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen. Transplantation (2004) 0.99

High-resolution CT findings of patients with pulmonary nocardiosis. J Thorac Dis (2012) 0.98

Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther (2004) 0.97

Early and definitive diagnosis of toxic shock syndrome by detection of marked expansion of T-cell-receptor VBeta2-positive T cells. Emerg Infect Dis (2003) 0.97

[Severe falciparum malaria with prolonged hemolytic anemia after successful treatment with intravenous artesunate]. Kansenshogaku Zasshi (2002) 0.96

Pseudoxanthomatous and xanthogranulomatous salpingitis of the fallopian tube: a report of four cases and a literature review. Int J Gynecol Pathol (2002) 0.96

Infective endocarditis with Lactococcus garvieae in Japan: a case report. J Med Case Rep (2011) 0.96

T cell treatment with small interfering RNA for suppressor of cytokine signaling 3 modulates allergic airway responses in a murine model of asthma. Am J Respir Cell Mol Biol (2010) 0.95

Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J Gastroenterol (2009) 0.95

Expression of membrane-bound and soluble receptor activator of NF-kappaB ligand (RANKL) in human T cells. Immunol Lett (2004) 0.94

The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. Immunol Lett (2004) 0.94

Paracrine IL-33 stimulation enhances lipopolysaccharide-mediated macrophage activation. PLoS One (2011) 0.93

Process for immune defect and chromosomal translocation during early thymocyte development lacking ATM. Blood (2012) 0.93

GITR ligand-costimulation activates effector and regulatory functions of CD4+ T cells. Biochem Biophys Res Commun (2008) 0.92

B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res (2010) 0.92

Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1. Infect Immun (2011) 0.92